for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eagle Pharmaceuticals Inc

EGRX.OQ

Latest Trade

43.12USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

33.85

 - 

64.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
43.12
Open
--
Volume
--
3M AVG Volume
3.67
Today's High
--
Today's Low
--
52 Week High
64.94
52 Week Low
33.85
Shares Out (MIL)
13.69
Market Cap (MIL)
592.02
Forward P/E
20.31
Dividend (Yield %)
--

Next Event

Eagle Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Eagle Pharmaceuticals Reports Q2 Loss Per Share Of $0.02

Eagle Pharmaceuticals Reports First Quarter 2020 Results

Eagle Pharma Announces Lab Test Results Demonstrating In Vitro Antiviral Activity Of Ryanodex Against Coronavirus Sars-Cov-2

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Industry

Biotechnology & Drugs

Contact Info

50 Tice Blvd Ste 315

WOODCLIFF LAKE, NJ

07677-7637

United States

+1.201.3265300

http://www.eagleus.com/

Executive Leadership

Michael Graves

Independent Chairman of the Board

David M. Pernock

President, Chief Operating Officer

Scott L. Tarriff

Chief Executive Officer, Director

Pete A. Meyers

Chief Financial Officer

Richard A. Edlin

Independent Director

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (USD)

2017

4.340

2018

3.870

2019

2.610

2020(E)

2.190
Price To Earnings (TTM)
268.13
Price To Sales (TTM)
3.08
Price To Book (MRQ)
3.24
Price To Cash Flow (TTM)
98.57
Total Debt To Equity (MRQ)
80.72
LT Debt To Equity (MRQ)
16.93
Return on Investment (TTM)
1.14
Return on Equity (TTM)
0.79

Latest News

Latest News

BRIEF-CMS Establishes Unique J-Code For Eagle Pharmaceuticals' PEMFEXY

* CMS ESTABLISHES UNIQUE J-CODE FOR EAGLE PHARMACEUTICALS' PEMFEXY (PEMETREXED FOR INJECTION)

BRIEF-Eagle Pharmaceuticals Reports First Quarter 2020 Results

* Q1 REVENUE $46 MILLION VERSUS REFINITIV IBES ESTIMATE OF $51.1 MILLION

Fed Circuit okays generic version of Eagle Pharma chemotherapy drug

Generic drug company Slayback Pharma LLC on Friday won an appeals court decision that clears the way for it to launch a generic version of the Eagle Pharmaceuticals Inc chemotherapy drug Belrapzo.

BRIEF-Eagle Pharma Advances Novel And Proprietary Formulation Of Fulvestrant Product Candidate Ea-114

* EAGLE PHARMACEUTICALS ADVANCES NOVEL AND PROPRIETARY FORMULATION OF FULVESTRANT PRODUCT CANDIDATE EA-114; COMPANY TO REQUEST ADDITIONAL MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (“FDA”) Source text for Eikon: Further company coverage:

BRIEF-Eagle Pharma Announces Lab Test Results Demonstrating In Vitro Antiviral Activity Of Ryanodex Against Coronavirus Sars-Cov-2

* EAGLE PHARMACEUTICALS ANNOUNCES LABORATORY TEST RESULTS DEMONSTRATING IN VITRO ANTIVIRAL ACTIVITY OF RYANODEX® (DANTROLENE SODIUM) AGAINST CORONAVIRUS SARS-COV-2

BRIEF-Eagle Pharmaceuticals - Board Approved Stock Buyback Of Up To $160 Million

* EAGLE PHARMACEUTICALS INC - BOARD APPROVED NEW SHARE REPURCHASE PROGRAM PROVIDING FOR REPURCHASE OF UP TO $160 MILLION OF COMMON STOCK

BRIEF-Eagle Pharmaceuticals - U.S. Court Affirmed Decision Requiring FDA To Grant Co, 7 Years Of Orphan Drug Exclusivity In U.S. For Bendeka

* EAGLE PHARMACEUTICALS - ON MARCH 13, U.S. COURT AFFIRMED DECISION REQUIRING FDA TO GRANT CO, 7 YEARS OF ORPHAN DRUG EXCLUSIVITY IN U.S. FOR BENDEKA Source text for Eikon: https://bit.ly/3aWM3Mb Further company coverage:

Eagle Pharma beats FDA on appeal over orphan drug marketing exclusivity

A federal appeals court on Friday ruled that the Food and Drug Administration wrongly failed to grant Eagle Pharmaceuticals Inc seven years of marketing exclusivity for its cancer treatment Bendeka after designating it as an "orphan drug" for rare diseases.

BRIEF-Eagle Pharma Reports Q4 Earnings Per Share Of $0.07

* EAGLE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE

BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53

* EAGLE PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 RESULTS

BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln

* EAGLE PHARMACEUTICALS INC SAYS CEO SCOTT TARRIFF'S 2017 TOTAL COMPENSATION WAS $8.04 MILLION VERSUS $7.15 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2HK04hV Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing

* IRIDIAN ASSET MANAGEMENT LLC REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF DEC. 31, 2017 - SEC FILING Source text: (http://bit.ly/2En48mt) Further company coverage:

BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals

* IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2AG5uGB) Further company coverage:

BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

* EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up